Thromboembolism in pregnancy: An overview

Current Opinion in Obstetrics and Gynecology

Volumn 8, Issue 6, 1996, Pages 458-463

  Girling, Joanna C ^b   De Swiet, Michael ^a  

^a QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTITHROMBIN III; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DEFECT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0030447674     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199612000-00013     Document Type: Review

References (48)

1. Report on Confidential Enquiry into Maternal Deaths in the United Kingdom 1991-1993. London: HMSO; 1996.
2. Beyth RJ, Cohen AM, Landefield C: Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995, 155:1031-1037.
3. Nelson-Piercy C, Peek MJ, de Swiet M: Obstetric physicians: are they needed? J R Coll Phys Lond 1996, 30:150-154.
4. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993, 90: 1004-1008.
5. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993, 342:1503-1506.
6. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994, 330:517-522.
7. de Stefano V, Leone G: Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologia 1995, 80:344-356.
8. Heijboer H, Brandjes DPM, Buller HR, Sturk A, ten Cate JW: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990, 323: 1512-1516.
9. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 1995, 346:1133-1134. This analysis of 1690 unrelated individuals from 24 different populations throughout the world shows a marked racial variation in the frequency of the factor V Leiden mutation: it is almost exclusively limited to White Europeans.
10. Kontula K, Ylikorkala A, Miettinen H: Arg506GIn factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995, 73:558-560.
11. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Combien F: Myocardial infarction, Arg 506 to GIn factor V mutation and activated protein C resistance [Letter]. Lancet 1995, 345:321.
12. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
13. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA: Association of idiopathic venous thromboembolism with single point-mutation at Arg 506 of factor V. Lancet 1994, 343:1535-1536.
14. Zoller B, Dahlback B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994, 343:1536-1538.
15. Esmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H: Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996, 347: 1374-1375.
16. Dahlback B: Are we ready for factor V Leiden screening? Lancet 1996, 347:1346-1347.
17. Wilde JT: The investigation of the patient with unexpected venous thrombosis. Postgrad Med J 1995, 71:720-724.
18. Walker ID, Hickman GM, Stevenson C, McCall F: High prevalence of 'APC resistance' in the presence of antiphospholipids. Br J Haematol 1994, 86(suppl 1):2.
19. Legnani C, Palareti G, Biagi R, Coccheri S: Activated protein C resistance in deep vein thrombosis. Lancet 1994, 343:541-542.
20. Dahlback B: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995, 85:607-614.
21. Vandenbroucke JP, Koster T, Briet E, Reitsman PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 344:1453-1457.
22. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FR, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet 1995, 346:1593-1596.
23. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995, 173:210-213. APCR was found in 60% of 34 Swedish women experiencing TED in pregnancy and 30% of 28 women in whom TED occurred while taking an oral contraceptive pill, compared with 10% of pregnant and non-pregnant controls.
24. Peek MJ, Nelson-Piercy C, Manning R, de Swiet M, Letsky EA: APCR and the incidence of the Leiden mutation in normal pregnancy. Br J Obstet Gynaecol 1996.
25. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffat K, Johnston M, Stevens P, Hirsh J: Antiphospholipid antibodies and venous thromboembolism. Blood 1995, 86:3685-3691. Important paper showing a lack of relationship between anticardiolipin antibodies and TED, but that the lupus anticoagulant is associated with TED.
26. Report of the RCOG Working Party on Prophylaxis against Thromboembolism in Gynaecology and Obstetrics. London: Chameleon Press Ltd; 1995. Gives the recommended use of thromboprophylaxis in association with caesarean section.
27. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H et al.: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thrombosis. N Engl J Med 1996, 332:1661-1665. A well conducted randomized study of almost 1000 subjects, suggesting that after short-term chronic phase treatment is completed, there is a sharp increase in the occurrence of further TED, which reaches a plateau at six months. This does not occur with longer-term chronic-phase treatment. Both the incidence of recurrence and the difference between the two groups may be most marked for those subjects with permanent risk factors.
28. Hirsh J: The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med 1996, 332:171-172.
29. Chesterman CN: After a first episode of thromboembolism. BMJ 1995, 311:700-701.
30. de Swiet M: Thromboembolism. In Medical Disorders in Obstetric Practice, edn 3. Edited by de Swiet M. Oxford: Blackwell Science; 1995:116-142. Up-to-date and extensive general review of the subject.
31. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR et al.: Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992, 326:975-982.
32. Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992, 339:441-445.
33. Barbour LA, Smith JM, Marlar RA: Heparin levels to guide thromboembolism prophylaxis in pregnancy. Am J Obstet Gynecol 1995, 173:1869-1873. Study of 14 pregnant women confirming that doses of unfractionated heparin will, depending on anti-Xa levels, need to be higher than in the non-pregnant subject if the same range is desired. There are still no trials of clinical outcome to determine the optimal dose.
34. Dahlman T: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265-1270.
35. Rizzoli R, Bonjour JP: Pregnancy-associated osteoporosis. Lancet 1996, 347:1274-1276.
36. Nelson-Piercy C: Low-molecular weight heparin for prophylaxis of thromboembolic disease during pregnancy. Current Obstet Med 1995, 3:147-158. Good, detailed account of the mechanisms of action of LMWH, its advantages and potential disadvantages.
37. Gillis S, Shushan A, Eldor A: Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynecol Obstet 1992, 39:297-301.
38. Rasmussen C, Wadt J, Jacobsen B: Thromboembolic prophylaxis with low molecular weight heparin in pregnancy. Int J Gynecol Obstet 1994, 47:121-125.
39. Dulitski M, Pauzner R, Langevitz P, Pras P, Pras M, Many A, Schiff E: Low-molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Am J Obstet Gynecol 1996, 87:380-383.
40. Sturridge F, Letsky EA, de Swiet M: The use of low molecular weight heparin for thromboprophylaxis in pregnancy. Br J Obstet Gynaecol 1994, 101:69-71.
41. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett J, Kakkar W: Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992, 68:652-656.
42. Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Riji AM, Prentice CRM, ten Cate JW: A comparative trial of a low molecular weight heparin (Enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995, 169:567-571.
43. Wiig JN, Solhaug JH, Bilberg T, Bjerkeset T, Edwin B, Gruner OP, Havig O, Holter O, Knudsen G, Lundblad R et al.: Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Eur J Surg 1995, 161:663-668.
44. Kakkar W, Cohen AT, Edmondson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkas S: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993, 341:259-265.
45. Buckley MM, Sorkin EM: Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992, 44:465-497.
46. Shefras J, Farquharson RG: Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996, 65:171-174. The loss of lumbar spine bone density during pregnancy is the same in women taking LMWH as in normal controls, is not dose-dependent, and recovers once lactation ceases.
47. Colligan F, Frydman A, Caplain H, Ozoux ML, le Roux Y, Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995, 73: 630-640.
48. Levine MN: Thrombolytic therapy for thromboembolism. Complications and contraindications. Clin Chest Med 1995, 16:321-328.